Andrew Jenner is Director General of INTERPAT – a global trade association of Chief IP Counsels from the biopharmaceutical industry that seeks to create sustainable innovation ecosystems to advance human health. He is also the Executive Director of a strategy and policy consultancy based in the UK.
He was previously the Executive Director of Corporate Strategy and Legal Affairs at the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) based in Geneva, where he deputised for the Director General. His main responsibilities included developing pharmaceutical industry strategy and policy development on priority issues. He also represented the industry within the UN and the World Trade Organization, leading a diverse team of policy, public affairs and legal professionals.
From 2007 to 2009 he was a Senior Policy Advisor and Head of the IP Crime Policy Group for the UK Intellectual Property Office (IPO), and led on the creation and implementation of an interagency strategy to combat counterfeiting and piracy.
From 2004 to 2007 he was Head of Trade & Development at the IPO and led the UK delegation within the World Trade Organization and the World Intellectual Property Organization. He was also the principle IP advisor to the EU on the World Health Organization’s negotiations on Public Health, Innovation and IP. He also led on policy relating to EU/UK IP pharmaceutical regulations, including the EU Regulation on the compulsory licensing, and implementation of the EU Human Medicines and Paediatric Medicines Regulations into UK law. He first joined the UK Government in 1998 as a patent examiner in medical and optical devices having previously worked in the automotive industry.
He is Chartered Manager (CMGR), a Fellow of the Chartered Institute of Management (FCMI), a Fellow the Royal Society of Arts (FRSA) and a Member of the Institute of Engineering & Technology (MIET) having a bachelor’s degree in Mechanical Engineering, and a Post-graduate and Master degrees in Law.